Oncology Update: Anamorelin. (18th August 2017)

• Record Type: Journal Article
• Authors: Prommer, Eric
• Is Part Of: Palliative care. Volume 10(2017)
• Publication Date: 2017-08-18
• Subjects: Anorexia -- cachexia -- ghrelin -- anamorelin -- handgrip strength; Palliative treatment -- Periodicals; Terminal care -- Periodicals; Palliative Care; Terminal Care; Palliative treatment; Terminal care; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.029
• DOI: 10.1177/1178224217726336
• Languages: English
• ISSNs: 1178-2242

Abstract

Background: Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis. Besides weight loss, patients experience a cluster of symptoms including anorexia, early satiety, and weakness. The 3 stages of cachexia include stages of precachexia, cachexia, and refractory cachexia. Refractory cachexia is associated with active catabolism or the presence of factors that make active management of weight loss no longer possible. Patients with refractory cachexia often receive glucocorticoids or megasterol acetate. Glucocorticoid effect is short and responses to megasterol are variable. Anamorelin is a new agent for cancer anorexia-cachexia, with trials completed in advanced lung cancer. Acting as an oral mimetic of ghrelin, it improves appetite and muscle mass. This article reviews the pharmacology, pharmacodynamics, and effect on cancer cachexia. Methods: A PubMed search was done using the Medical Subject Headings term anamorelin. Articles were selected to provide a pharmacologic characterization of anamorelin. Results: Anamorelin increases muscle mass in patients with advanced cancer in 2-phase 3 trials. Conclusions: Anamorelin improves anorexia-cachexia symptoms in patients with advanced non–small-cell lung cancer.